




ANGLE

**Preliminary Results for the year
ended 30 April 2014**

CE Mark awarded and system deployed
with key opinion leaders

Andrew Newland and Ian Griffiths
23 July 2014





Legal disclaimer

The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment (without notice), verification and completeness.

This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided to recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether orally or in writing, in connection with the Company. Neither this document or any part of this document nor any copy of it may be sent to or taken into the United States of America, Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland, nor may it be distributed to, directly or indirectly, to any US person (within the meaning of regulation S promulgated under the United States Securities Act of 1933, (as amended) (the "US Securities Act")). This document does not constitute an offer to buy or to subscribe for, or the solicitation of an offer to buy or to subscribe for securities in the Company. To the extent this document is received or used in jurisdictions outside the UK, any such recipient or user should inform themselves about and observe any applicable legal requirements. Neither this document nor any part of this document should be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronic transmission, to persons with addresses in the United States of America (or any of its territories or possessions) Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any citizens, residents or nationals thereof, or to any corporation, partnership or other entity created or organised under the laws thereof or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Any such distribution could result in violation of the laws of such countries.

This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to purchase any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for any purpose whatsoever on the information, representation or opinions.

This document should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

Forward-Looking Statements

This presentation and the associated commentary contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve significant risks and uncertainties. These statements are based on information currently available to the Company; and actual results could differ materially from those stated or implied, due to risks and uncertainties associated with its business. Forward-looking statements include statements regarding expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "potential", "target", "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "should", "will", and "would" or similar words. ANGLE assumes no obligation to update the information included in this presentation, whether as a result of new information, future events or otherwise.



Highlights

- ❖ Balance sheet strengthened by sale of Geomerics
- ❖ Parsortix system successfully deployed with key opinion leaders
- ❖ CE Mark awarded for clinical use in Europe
- ❖ Partnership established with Medical Research Council's cancer unit at the University of Cambridge
- ❖ Intellectual property further strengthened
- ❖ Extensive in depth evaluation completed by Cancer Research UK Manchester Institute
- ❖ ANGLE now focused on key opinion leaders, securing US regulatory authorisation and clinical data

Financial Results for the year ended 30 April 2014

| | 2014 | 2013 |
|-----------------------------------|---------|---------|
| Statement of Comprehensive Income | £'000 | £'000 |
| Revenue | 801 | 969 |
| Investments portfolio gain | 1,334 | 514 |
| | 2,135 | 1,483 |
| Operating costs | (3,485) | (2,555) |
| Other income | 112 | 41 |
| Loss before tax | (1,238) | (1,031) |
| Statement of Financial Position | 30Apr14 | 30Apr13 |
| Investments | 601 | 3,961 |
| Trade and other receivables | 328 | 454 |
| Inventories | 52 | 62 |
| Cash | 3,898 | 1,828 |
| Property, plant and equipment | 139 | 138 |
| Intangible assets | 1,142 | 1,080 |
| Total assets | 6,160 | 7,523 |

Comments

-  Continued investment principally in Parsortix of £3.0m
 - Operating costs £2.8m
 - Capitalised expenditure £0.2m

-  Geomerics non-core investment sold for £6.2m
 - £5.5m received
 - £0.7m retention

-  Cash position strengthened to £3.9m

Personalised cancer care

- ❖ Incidence of cancer growing
 - 14 million new cases in 2012 up from 12.7 million cases in 2008
 - 8.2 million deaths up from 7.6 million
- ❖ Characteristic of cancer is that it continually evolves and mutates
 - Each patient's cancer is different
 - The individual patient's cancer changes over time
- ❖ Effective treatment requires personalised care
 - Understanding patient's cancer
 - Selecting drugs that target their specific cancer
 - Advanced analytical techniques provide the key
- ❖ Healthcare economic pressures
 - Efficient and effective use of resources
- ❖ Major pharma are developing much more selective drugs
 - Colorectal cancer KRAS+ Cetuximab
 - Lung cancer EGFR+ Iressa
 - Breast cancer HER2+ Herceptin

Obtaining cancer cells for analysis

Existing approach: solid tumour biopsy

- ❖ Clinicians cut out the tumour and analyse the cancer cells
 - Breast cancer mastectomy or lumpectomy
 - Colorectal cancer colonoscopy tumour biopsy
 - Prostate cancer fine needle biopsy and prostatectomy
- ❖ Difficulty in accessing some tumours
 - Pancreatic cancer
 - Lung cancer
 - Brain cancer
- ❖ Repeat tumour biopsy to see how the cancer may have changed is problematic as tissue not available for excision
- ❖ Side effects and treatment delays

New approach: “liquid biopsy” retrieve cancer cells from blood

- ❖ Intense medical interest in liquid biopsy
- ❖ Non-invasive; Repeatable; Cost effective
- ❖ Challenge is only one circulating tumour cell (CTC) in one billion blood cells

Key Opinion Leaders

ANGLE has formal research relationships with three leading UK institutions:



- ◆ Positive evaluation. Key advantages:
 - High level of capture (80-100%) and harvest (60-100%)
 - Does not use antibody capture
 - Exceptionally low WBC contamination
 - Harvested cells can be analysed
- ◆ Colorectal cancer patient validation
 - High CTC capture rate
 - Parsortix system demonstrated twice the sensitivity of currently accepted clinical practice for CTC capture
- ◆ Partnership to establish a Cambridge Parsortix laboratory
 - Bowel cancer including colorectal, pancreatic and oesophageal cancers
 - New drug compounds
 - Gene mutation analysis and next-generation sequencing (NGS)



Competitive advantages of Parsortix

- ❖ Parsortix patented step system is simple, effective and affordable
 - Captures a high proportion of CTCs
 - Can be used with all solid tumour cancers (including breast, prostate, lung, colorectal, pancreatic, ovarian, cervical, brain)
 - Captured CTCs are intact, viable and undamaged
 - CTCs can be harvested (recovered from system) for analysis
 - Purity of CTCs very high (i.e. very low background contamination from white blood cells) allowing direct molecular analysis of harvested cells

- ❖ System does not use antibodies to capture cells
 - Antibody systems miss key target cells such as mesenchymal cells
 - Antibody systems do not work at all for some cancers such as ovarian cancer
 - Antibody capture can compromise downstream molecular analysis
 - Antibody systems are complicated and expensive

- ❖ System does not use membranes to capture cells
 - Membrane systems can clog up and have high background contamination
 - Membrane systems cannot easily harvest CTCs for analysis



Commercial advantages of Parsortix

- ❖ FDA submission in March – targeting authorisation by end Q3
 - Capture large cells in blood for molecular analysis
 - **Potential to be the first FDA authorised CTC harvesting system**

- ❖ In-house not CLIA (certified laboratory) remote service
 - Offer the hospitals a system that they can use in their own labs
 - Competitor systems very complicated and not FDA approved so can only offer a remote service

- ❖ No need for reimbursement codes
 - Our system is a lab tool and can be used immediately for treating patients
 - Other closed systems need a reimbursement code that will take 3-6 years to secure and be very expensive

- ❖ Open source with wide application
 - All solid cancers and all applications
 - Designed to work with existing medtech platforms (not to compete with them)
 - Clear route to market

Scientific Advisory Board

- ◆ Prof Adrian Newland, Barts Health NHS Trust
 - haematology, cancer diagnostics and National Institute for Clinical Excellence (NICE)

- ◆ Dr Clive Stanway, Cancer Research Technology
 - cancer drug development and major pharma

- ◆ Dr Harold Swerdlow, New York Genome Center
 - next-generation sequencing

- ◆ Prof Ashok Venkitaraman, Medical Research Council's Cancer Cell Unit
 - cancer cell biology and personalised cancer care



Objectives achieved during the year

- ❖ Strengthen balance sheet with sale of Geomerics - **achieved**
- ❖ Place Parsortix system with key opinion leaders – **ongoing**
- ❖ 3rd party validation of the Parsortix system - **achieved**
- ❖ Select a manufacturing partner and establish quality control systems - **achieved**
- ❖ Plan for regulatory authorisation for the product to be used in the clinical market - **achieved**
- ❖ CE Mark authorisation for clinical sales in the Europe - **achieved**
- ❖ Application to the FDA for authorisation for clinical sales in the United States - **achieved**
- ❖ Key opinion leader market entry plan for Parsortix - **achieved**



How ANGLE intends to secure its market position

- ◆ Further roll-out with key opinion leaders
- ◆ FDA authorisation target end of Q3 2014
- ◆ Sales into the research market
- ◆ Key opinion leader reporting
- ◆ Clinical applications supported by pilot studies
- ◆ Patient studies to support clinical applications
- ◆ Roll out of clinical sales

Parsortix system + regulatory authorisation + clinical application + patient data + key opinion leader = \$bn market

Personalised cancer care



"Personalised medicine is the most exciting change in cancer treatment since the invention of chemotherapy"

Professor Peter Johnson, Chief Clinician, Cancer Research UK

"The evaluation phase of our work is now successfully complete and we see great promise in the application of the Parsortix technology for harvesting CTCs for molecular analysis to enable personalised cancer care. We are now undertaking pilot studies using the Parsortix system in both colorectal cancer and pancreatic cancer."

Deputy and Genomics Leader within the Clinical & Experimental Pharmacology group at Cancer Research UK Manchester Institute, Ged Brady

"This agreement will greatly facilitate the use of ANGLE's Parsortix system in our research, and that of other colleagues in Cambridge. **We foresee several exciting research avenues to test different applications of the Parsortix system in the diagnosis and personalised treatment of cancer.**"

Medical Research Council Cancer Unit Director, Professor Ashok Venkitaraman

National Cancer Institute
at the National Institutes of Health

"Personalized cancer care is the future of medicine. The faster we can develop cancer treatments that are tailored to the individual characteristics of each patient, the better we can concentrate interventions on those who will benefit the most from them and avoid the expense, side effects and emotional involvement on those who will not."



Contact details

Andrew Newland

ANGLE plc

3 Frederick Sanger Road

The Surrey Research Park

Guildford GU2 7YD

United Kingdom

Tel: +44 1483 685830

Fax: +44 1483 685836

Email: andrew.newland@ANGLEplc.com

Website: www.ANGLEplc.com